表紙
市場調查報告書

美國通用抗癌劑市場預測

US Cancer Generics Market Outlook 2022

出版商 KuicK Research 商品編碼 448762
出版日期 內容資訊 英文 100 Pages
商品交期: 最快1-2個工作天內
價格
美國通用抗癌劑市場預測 US Cancer Generics Market Outlook 2022
出版日期: 2017年02月24日內容資訊: 英文 100 Pages
簡介

本報告針對美國通用抗癌劑市場調查分析、提供美國通用藥品藥事法、健康保險情況、品牌/非品牌通用藥品、市場概要、未來預測整體資訊。

第1章 通用抗癌劑:溫和養生

  • 介紹
  • 需要通用製劑的理由
  • 通用抗癌劑優點

第2章 美國通用藥品法規

  • Hatch-Waxman法案 (1984年)
  • 通用藥品歷史

第3章 通用抗癌劑專利

  • 美國通用藥品藥事相關法規
  • 美國通用抗癌劑的專利戰爭

第4章 美國處方藥對經濟的負擔

  • 抗癌劑的高成本
  • 通用醫藥品節省醫療費

第5章 通用抗癌劑:美國市場依然高價

  • 無人購買技術革新也沒有意義
  • 美國通用藥品爭吵的理由

第6章 美國健康保險情況與癌症

  • 提供抗癌劑補償
  • 民間健康保險選項
  • 政府資金的保險

第7章 品牌/非品牌通用醫藥品

  • 市場的認可通用藥品訪問
  • 未認可的通用規範

第8章 腫瘤通用藥品

  • 抗癌標的治療藥
  • 單克隆抗體通用醫藥品狀況
  • 小分子抑製劑通用醫藥品改革

第9章 美國FDA承認的通用抗癌劑

  • Taxotere (Docetaxel通用藥品)
  • Imatinib (Glivec通用藥品)
  • Sorafinib (Nexavar通用藥品)

第10章 美國通用抗癌劑市場概要

  • 美國通用抗癌劑市場介紹
  • 歐洲通用藥品市場
  • 亞洲通用藥品市場

第11章 美國通用抗癌劑市場力學

  • 市場促進因素
  • 阻礙

第12章 美國通用抗癌劑市場未來預測

目錄

"US Cancer Generics Market Outlook 2022" report gives comprehensive insight on the various indicators and trend analysis related to the emergence and integration of cancer generics drugs in mainstream pharmaceutical market in US. The report analyzes various clinical and non-clinical parameters responsible for the growth on cancer generics drugs in recent years. The introduction of generics has resulted in saving of billions of dollars for various stake holders involved US cancer drug market. It is expected that total savings from generics in cancer therapy (in treatment & post treatment) will surpass US$ 30 Billion by 2022 and will further give the required thrust to adoption of generics drugs in cancer therapy as compare to prescribed branded drugs.

Even though most of the attention and spending in the oncology segment in the US has been focused on the remarkable scientific inventions of the newer targeted drugs but the overburdening of the economic high cost of cancer drugs has made US to follow up the line of generics. Certainly, after the existence of Hatch-Waxman Act, the entries of generic products were acceptable between the Americans.

The beneficial aspects of generic regimens are already well established, as the delivery of equal therapeutic efficacy in low price is the principal aim of cancer generics. The cost for patented oncological drugs and the generic drugs have wide gap which is getting shorter with the emerging patent cliff for cancer drugs in US and the arrival of the cancer generics era.

Concerning the cost, indeed cancer generics provide an exceptional solution towards high cost, yet the scenario is different for the Americans. However, in US cancer generics cost much higher in contrary to the other nations, reason being is the no negotiation mode of government in the pharmaceutical sector. The prices paid for generics in US are many fold higher than developing countries like India and China.

Certainly, among the developed nations the usage and prescription of generics is quite higher depicting the greater medical needs due to overburden of massive diseases and cancer is one of them. The demand for cancer generics is so high that the trend has created a shortage landscape. It is a part of the problem of the scarcity of generics across all medical specialties, but its oncology is particularly vulnerable. The reason of the shortages is multi-factorial but is largely economic and is due to the lack of incentives to produce generics.

"US Cancer Generics Market Outlook 2022" report highlights:

  • Introduction to Cancer Generics
  • US Generic Drugs Legislature
  • US Health Insurance Scenario & Cancer
  • Aspects of Branded & Non-Branded Generics
  • US Cancer Generics Market Overview

Table of Contents

1. Cancer Generics: A Modest Regimen

  • 1.1 Introduction to Cancer Generics
  • 1.2 Why There Exist is Need for Generic Forms?
  • 1.3 Supremacy of Cancer Generic Drugs
    • 1.3.1 Cost
    • 1.3.2 Quality & Safety
    • 1.3.3 Large Number of Manufacturer
    • 1.3.4 Approved by FDA
    • 1.3.5 Concerns in Cancer Generic Medication

2. US Generic Drugs Legislature

  • 2.1 Hatch-Waxman Act, 1984
  • 2.2 The Generic Drugs Chronological Disgrace

3. Trail towards Patenting of Cancer Generic Drugs

  • 3.1 US Generic Pharmaceutical Regulation
  • 3.2 Patenting Wars of Cancer Generics in US

4. Economic Burden of Prescription Drugs in US

  • 4.1 High Cost of Cancer Drugs
  • 4.2 Healthcare Savings by Virtue of Generics

5. Cancer Generic Drugs: Still Overpriced in US Market

  • 5.1 Innovation is Meaningless if Nobody can Afford It
  • 5.2 Why US Contends More in Generics?

6. US Health Insurance Scenario & Cancer

  • 6.1 Provisions for Cancer Drug Coverage
  • 6.2 Private Health Insurance Options
  • 6.3 Government Funded Insurance

7. Aspects of Branded & Non-Branded Generics

  • 7.1 Debut of Authorized Generics in Market
  • 7.2 Anti-Authorized Generic Legislation

8. Generics in Oncology World

  • 8.1 Anti-Cancer Targeted Therapy Drugs
  • 8.2 Status of Generics in Monoclonal Antibodies
  • 8.3 Crusade of Small Molecule Inhibitor towards Generics

9. FDA Approved Anti-Cancer Generics in US

  • 9.1 Taxotere (Generic Docetaxel)
  • 9.2 Imatinib (Generic Glivec)
  • 9.3 Sorafinib ( Generics Nexavar)

10. US Cancer Generics Market Overview

  • 10.1 US Cancer Generics Market Introduction
  • 10.2 Europe Generics Market Contrary to US
  • 10.3 Asia Generics Market Contrary to US

11. Cancer Generics Drug Market Dynamics

  • 11.1 Accelerative Parameters
    • 11.1.1 Expiration of Patents
    • 11.1.2 Unaffordability of Cancer Drugs
    • 11.1.3 Cost Containment by Government
    • 11.1.4 Generic Drug User Fee Amendments (2012)
    • 11.1.5 High Cancer Risk & Aging Population of US
  • 11.2 Pitfalls Confronted by Generic Industry

12. US Cancer Generics Market Future Prospect

List of Figures

  • Figure 1-1: US - Savings through Generic Drug usage (US$ Billion), 2010-2015
  • Figure 1-2: Zofran- Price of Branded & Generic Pill (US$)
  • Figure 1-3: Illustration of Pros & Cons of Generic Drugs
  • Figure 2-1: Interests of Brand drug & Generic Drug Industry over Hatch-Waxman Act
  • Figure 3-1: Major Exclusivity under the NDA Statutory Requirements
  • Figure 3-2: Demonstration of Bringing Generic Drug into Market
  • Figure 3-3: US - FDA Rules for Generics Production
  • Figure 4-1: Branded V/S Generic Prescription Drug Revenues (2005-2015)
  • Figure 4-2: US - Expected Cost Savings through Generics in Cancer Therapy (US$ Billion), 2016-2022
  • Figure 4-3: US - Potential Cost Saving Across Biologics in
  • Figure 5-1: US - Representation of Generic Cost of Gleevac
  • Figure 6-1: Distribution of Medicare Savings in FY2016 Budget
  • Figure 6-2: Cost Sharing of Generic Drug in Medicare Part D Coverage Gap (%), 2015-2020
  • Figure 6-3: Various Medicare Beneficiaries Provided by US Government
  • Figure 6-4: US - Share of Medicare & Self Payment for Generics Drug (%)
  • Figure 7-1: Illustration of the Profits Earned During the 180-Day Exclusivity
  • Figure 7-2: Strategies for Launching Authorized Generics in Market
  • Figure 8-1: US - Proportion of Branded & Generic Drug Revenues (%), 2010-2015
  • Figure 8-2: FDA Approved Monoclonal Antibodies in Cancer Therapeutics
  • Figure 8-3: Development Cost of Generics v/s Biosimilar
  • Figure 9-1: Cost Comparison of Gleevac in Branded & Generic Versions
  • Figure 9-2: Naxawar Price Difference in Generic & Branded Version
  • Figure 10-1: Global - Top Generics Manufacturers Based on Revenues (US$ Billion), 2015
  • Figure 10-2: US - Generics Drug Market Opportunity (US$ Billion). 2016-2022
  • Figure 10-3: US - Savings through Generic Drug usage in (US$ Billion), 2017-2022
  • Figure 10-4: US - Share of Leading Generic Companies
  • Figure 11-1: Major Accelerative Parameters for the Growth of Generic Market
  • Figure 11-2: Current Challenges Faced by Generic Pharmaceutical